Vision-related quality of life outcomes in the BEVORDEX study: A clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema

C Aroney; S Fraser-Bell; EL Lamoureux; MC Gillies; LL Lim; EK Fenwick

Journal article

Vision-related quality of life outcomes in the BEVORDEX study: A clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema

C Aroney, S Fraser-Bell, EL Lamoureux, MC Gillies, LL Lim, EK Fenwick

Investigative Ophthalmology and Visual Science | ASSOC RESEARCH VISION OPHTHALMOLOGY INC | Published : 2016

DOI: 10.1167/iovs.16-19729

Abstract

PURPOSE. To determine the patient-centered effectiveness of treatment with the slow-release dexamethasone intravitreal implant (DEX implant) and intravitreal bevacizumab using the Impact of Vision Impairment Questionnaire (IVI), a vision-related quality of life (VRQoL) measure, in patients with visual impairment secondary to center-involving diabetic macular edema (DME). METHODS. Patients with DME were enrolled in a phase 2, prospective, multicenter, randomized, single-masked clinical trial and received either DEX implant 4 monthly or bevacizumab monthly, both pro re nata. Vision-related quality of life was measured at baseline and 24 months, using the IVI’s three component scales, namely re..

View full abstract

University of Melbourne Researchers

Ecosse Lamoureux Author

Lyndell Lim Author

Grants

Funding Acknowledgements

Supported by grants from the National Health and Medical Research Council (NHMRC; Canberra, ACT, Australia), which was supplemented by an unrestricted educational grant from Allergan Pharmaceuticals (Irvine, CA, USA), and a NHMRC Clinical Fellowship (MCG).